CPI-1205 is under clinical development by MorphoSys and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CPI-1205’s likelihood of approval (LoA) and phase transition for Lymphoma took place on 05 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CPI-1205 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CPI-1205 overview

CPI-1205 is under development for the treatment of metastatic castration-resistant prostate cancer and B-Cell lymphomas including follicular lymphoma, diffuse large B cell lymphoma and marginal zone lymphomas. The drug candidate is administered orally. It belongs to pyridone family and targets the EZH2 (histone methyltransferase (HMT) subunit of the Polycomb Repressor complex 2 (PRC2)). It was also under development for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, metastatic transitional (urothelial) tract cancer, multiple myeloma.

MorphoSys overview

MorphoSys is commercial-stage biopharmaceutical company that develop monoclonal antibodies for therapeutic and research applications, with focused on the treatment of cancer and autoimmune diseases. The company’s product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. MorphoSys also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products. It operates in the US. MorphoSys is headquartered in Planegg, Bayern, Germany.

Quick View CPI-1205 LOA Data

Report Segments
  • Innovator
Drug Name
  • CPI-1205
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: MorphoSys
  • Originator: Constellation Pharmaceuticals
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.